Kenvue (NYSE:KVUE) Posts Earnings Results, Meets Expectations

Kenvue (NYSE:KVUE) announced its quarterly earnings data on Thursday. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.26, Zacks reports. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. Kenvue updated its FY 2025 guidance to 1.440-1.469 EPS.

Kenvue Price Performance

Shares of NYSE:KVUE traded up $0.30 on Friday, hitting $20.10. The company’s stock had a trading volume of 6,644,957 shares, compared to its average volume of 12,328,604. The company has a 50-day simple moving average of $21.61 and a 200 day simple moving average of $21.93. Kenvue has a 1 year low of $17.67 and a 1 year high of $24.46. The company has a market capitalization of $38.53 billion, a PE ratio of 36.54, a PEG ratio of 2.05 and a beta of 1.45. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be issued a $0.205 dividend. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 4.08%. Kenvue’s payout ratio is currently 149.09%.

Analyst Ratings Changes

KVUE has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and dropped their price target for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. UBS Group reduced their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a report on Friday. Royal Bank of Canada reissued a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a report on Monday. Piper Sandler raised Kenvue from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $21.00 to $26.00 in a report on Monday, January 6th. Finally, Bank of America raised their price objective on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Kenvue currently has a consensus rating of “Hold” and an average price target of $22.92.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.